FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4319242172> ?p ?o ?g. }

• W4319242172 abstract "Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a hepatic enzyme that regulates blood cholesterol levels by degrading low-density lipoprotein (LDL) receptors from the surface of hepatocytes. Studies have shown that inhibiting this molecule decreases the cardiovascular risk in individuals with atherosclerotic cardiovascular disease (ASCVD) by lowering low-density lipoprotein cholesterol (LDL-C). Two major cardiovascular outcome trials showed that the use of the PCSK9 inhibitors (alirocumab and evolocumab) in patients with recent acute coronary syndrome (ACS) is associated with a lower risk of further cardiovascular (CV) events. Information regarding the use of these monoclonal antibodies for primary prevention has also been reported by these trials. The goal of this systematic review is to describe the mechanism of PCSK9 inhibitors and further discuss their ability to reduce CV risk in high-risk populations. The search strategy was used in a systematic way using PubMed Central, Google Scholar, and ScienceDirect. We included randomized control trials (RCTs), systematic reviews, and narrative reviews in English published in the last five years. Observational studies, case reports, and case studies were excluded. The quality of the studies was evaluated using the Cochrane Collaboration Risk of Bias Tool, Assessment of Multiple Systematic Reviews 2, and Scale for the Assessment of Narrative Review Articles. A total of 10 articles were included in this systematic review. These included an RCT, a systematic review, and eight narrative reviews. Our study suggested that adding PCSK9 inhibitors to background statin therapy for selected patients with high-risk factors demonstrated substantial benefits in reducing overall CV morbidity and mortality after ACS. Multiple studies have demonstrated the short-term safety of low LDL-C levels caused by these drugs. However, long-term safety must be assessed with further studies." @default.
• W4319242172 created "2023-02-05" @default.
• W4319242172 creator A5000269203 @default.
• W4319242172 creator A5002872904 @default.
• W4319242172 creator A5009223160 @default.
• W4319242172 creator A5013799037 @default.
• W4319242172 creator A5014015399 @default.
• W4319242172 creator A5015592109 @default.
• W4319242172 creator A5029504987 @default.
• W4319242172 creator A5033277073 @default.
• W4319242172 creator A5043816650 @default.
• W4319242172 creator A5056854497 @default.
• W4319242172 creator A5066174592 @default.
• W4319242172 creator A5066190248 @default.
• W4319242172 creator A5066803607 @default.
• W4319242172 date "2023-02-05" @default.
• W4319242172 modified "2023-10-04" @default.
• W4319242172 title "Reduction of Cardiovascular Risk Using Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Acute Coronary Syndrome: A Systematic Review" @default.
• W4319242172 cites W1898803325 @default.
• W4319242172 cites W2768588165 @default.
• W4319242172 cites W2792390052 @default.
• W4319242172 cites W2804593230 @default.
• W4319242172 cites W2810481936 @default.
• W4319242172 cites W2848978533 @default.
• W4319242172 cites W2899810284 @default.
• W4319242172 cites W2899997727 @default.
• W4319242172 cites W2908219532 @default.
• W4319242172 cites W2914416905 @default.
• W4319242172 cites W2921346491 @default.
• W4319242172 cites W2973253443 @default.
• W4319242172 cites W2983158177 @default.
• W4319242172 cites W3000712048 @default.
• W4319242172 cites W3004421876 @default.
• W4319242172 cites W3030779414 @default.
• W4319242172 cites W3033404795 @default.
• W4319242172 cites W3033713772 @default.
• W4319242172 cites W3046033709 @default.
• W4319242172 cites W3081988264 @default.
• W4319242172 cites W3103325438 @default.
• W4319242172 cites W3120916426 @default.
• W4319242172 cites W3140974984 @default.
• W4319242172 cites W3144543375 @default.
• W4319242172 cites W3146142859 @default.
• W4319242172 cites W4213436893 @default.
• W4319242172 cites W4281261930 @default.
• W4319242172 doi "https://doi.org/10.7759/cureus.34648" @default.
• W4319242172 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36895542" @default.
• W4319242172 hasPublicationYear "2023" @default.
• W4319242172 type Work @default.
• W4319242172 citedByCount "0" @default.
• W4319242172 crossrefType "journal-article" @default.
• W4319242172 hasAuthorship W4319242172A5000269203 @default.
• W4319242172 hasAuthorship W4319242172A5002872904 @default.
• W4319242172 hasAuthorship W4319242172A5009223160 @default.
• W4319242172 hasAuthorship W4319242172A5013799037 @default.
• W4319242172 hasAuthorship W4319242172A5014015399 @default.
• W4319242172 hasAuthorship W4319242172A5015592109 @default.
• W4319242172 hasAuthorship W4319242172A5029504987 @default.
• W4319242172 hasAuthorship W4319242172A5033277073 @default.
• W4319242172 hasAuthorship W4319242172A5043816650 @default.
• W4319242172 hasAuthorship W4319242172A5056854497 @default.
• W4319242172 hasAuthorship W4319242172A5066174592 @default.
• W4319242172 hasAuthorship W4319242172A5066190248 @default.
• W4319242172 hasAuthorship W4319242172A5066803607 @default.
• W4319242172 hasBestOaLocation W43192421721 @default.
• W4319242172 hasConcept C126322002 @default.
• W4319242172 hasConcept C168563851 @default.
• W4319242172 hasConcept C17744445 @default.
• W4319242172 hasConcept C177713679 @default.
• W4319242172 hasConcept C189708586 @default.
• W4319242172 hasConcept C199539241 @default.
• W4319242172 hasConcept C23131810 @default.
• W4319242172 hasConcept C2776478404 @default.
• W4319242172 hasConcept C2776839432 @default.
• W4319242172 hasConcept C2777698277 @default.
• W4319242172 hasConcept C2778114629 @default.
• W4319242172 hasConcept C2778163477 @default.
• W4319242172 hasConcept C2778824825 @default.
• W4319242172 hasConcept C2778849439 @default.
• W4319242172 hasConcept C2779473830 @default.
• W4319242172 hasConcept C2780072125 @default.
• W4319242172 hasConcept C2780745583 @default.
• W4319242172 hasConcept C2780902209 @default.
• W4319242172 hasConcept C2780948078 @default.
• W4319242172 hasConcept C43554185 @default.
• W4319242172 hasConcept C500558357 @default.
• W4319242172 hasConcept C60644358 @default.
• W4319242172 hasConcept C71924100 @default.
• W4319242172 hasConcept C86803240 @default.
• W4319242172 hasConcept C95190672 @default.
• W4319242172 hasConceptScore W4319242172C126322002 @default.
• W4319242172 hasConceptScore W4319242172C168563851 @default.
• W4319242172 hasConceptScore W4319242172C17744445 @default.
• W4319242172 hasConceptScore W4319242172C177713679 @default.
• W4319242172 hasConceptScore W4319242172C189708586 @default.
• W4319242172 hasConceptScore W4319242172C199539241 @default.
• W4319242172 hasConceptScore W4319242172C23131810 @default.
• W4319242172 hasConceptScore W4319242172C2776478404 @default.
• W4319242172 hasConceptScore W4319242172C2776839432 @default.
• W4319242172 hasConceptScore W4319242172C2777698277 @default.

• next